The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. [electronic resource]
Producer: 20100430Description: 803-9 p. digitalISSN:- 1432-1335
- Adenocarcinoma -- blood
- Adult
- Aged
- Analysis of Variance
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- blood
- Camptothecin -- administration & dosage
- Colorectal Neoplasms -- blood
- DNA Repair -- drug effects
- DNA-Binding Proteins -- genetics
- Female
- Follow-Up Studies
- Genetic Predisposition to Disease
- Genotype
- Humans
- Irinotecan
- Male
- Middle Aged
- Neoplasm Staging
- Polymorphism, Single Nucleotide
- Predictive Value of Tests
- Prospective Studies
- Survival Analysis
- Treatment Outcome
- X-ray Repair Cross Complementing Protein 1
- Xeroderma Pigmentosum Group D Protein -- genetics
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.